Expression of estrogen receptors in epithelial ovarian carcinoma

Loading...
Thumbnail Image

Date

01/01/2018

Journal Title

Journal ISSN

Volume Title

Type

Article

Publisher

Medknow Publications

Series Info

Journal of The Arab Society for Medical Research;Volume : 13 | Issue : 1 | Page : 71-78

Scientific Journal Rankings

Abstract

Background/aim Epithelial ovarian cancer accounts for ∼3% of female cancers. Steroid hormones such as estrogen and progesterone are thought to play an important role in the process of carcinogenesis of ovarian tumors. There are two subtypes of the nuclear estrogen receptor (ER-α and ER-β) encoded by separate genes. This work aimed to evaluate the expression pattern of ER-α and ER-β in epithelial ovarian carcinoma and their correlation with tumor histopathological parameters and proliferating cell nuclear antigen expression as a proliferation marker. Materials and methods A total of 50 cases of epithelial ovarian carcinoma were included in this study. All cases were female patients who underwent oophorectomies or subtotal or total hysterectomies with oophorectomies. Surgical specimens were sent to Pathology Department at Kasr El-Aini hospitals and to private laboratories. The cases were graded and staged according to WHO systems. The cases were stained by hemotoxylin and eosin for histopathological grading, and they were immunohistochemically stained for ER-α, ER-β, and proliferating cell nuclear antigen using streptavidin–biotin technique. Results In this study, 56% of cases were positively stained for ER-α. It is significantly correlated with both of the tumor histological type and proliferative state of the tumors. There was a significant inverse correlation between ER-α expression and the tumor histological grade. Approximately 62% of cases were positively stained for ER-β. There was a significant inverse correlation between ER-β positivity and both of the tumor stage and proliferative state of ovarian carcinoma cases. Conclusion The loss of ER-β, not ER-α, expression in ovarian tumors may be a feature of malignant transformation suggesting its potential role as tumor suppressor gene. Determination of ER subtypes may improve response to hormonal therapy using a selective ER modulator in selected cases of ovarian carcinoma.

Description

Keywords

University for Keywords: estrogen receptor-α, estrogen receptor-β, immunohistochemistry, ovarian carcinoma, proliferating cell nuclear antigen

Citation

Treviño LS, Johnson PA. Estrogen receptor subtype expression is altered in the Hen Model of Ovarian Cancer. J Mol Genet Med 2016; 10:203–208. Back to cited text no. 1 2. Mokhtar N, Gouda I, Adel I. Cance pathology registry and time trend analysis 2003-2004. Cairo, Egypt: Department of Pathology, NCI. 2007; 8:77–82. Back to cited text no. 2 3. Naik PS, Deshmukh S, Khandeparkar SGS, Joshi A, Babanagare S, Potdar J, Risbud NS. Epithelial ovarian tumors: clinicopathological correlation and immunohistochemical study. J Midlife Health 2015; 6:178–183. Back to cited text no. 3 4. Sylvia MT, Kumar S, Dasari P. The expression of immune-histochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol 2012; 55:33–37. Back to cited text no. 4 [Full text] 5. Jönsson JM, Arildsen NS, Malander S, Hartman AML, Nilbert M, Hedenfalk I. Sex steroid hormone receptor expression affects ovarian cancer survival. Transl Oncol 2015; 8:424–433. Back to cited text no. 5 6. Simpkins F, Garcia-Soto A, Slingerland J. New insights on the role of hormonal therapy in ovarian cancer. Steroids 2013; 78:530–537. Back to cited text no. 6 7. Buchynska LG, Iurchenko NP, Grinkevych VM, Nesina IP, Chekhun SV, Svintsitsky VS. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. Exp Oncol 2009; 31:48–51. Back to cited text no. 7 8. Lindgren PR, Cajander S, Backstrom T, Gustafsson JA, Makela S, Olofsson JI. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 2004; 221:97–104. Back to cited text no. 8 9. Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Bruning A. The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ER beta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther 2008; 7:1460–1467. Back to cited text no. 9 10. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A, Mor G. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol 2000; 96:417–421. Back to cited text no. 10 11. Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol 2003; 189:22–27. Back to cited text no. 11 12. Burges A, Bruning A, Dannenmann C, Blankenstein T, Jeschke U, Shabani N et al. Prognostic significance of estrogen receptor alpha and betaexpression in human serous carcinomas of the ovary. Arch Gynecol Obstet 2010; 281:511–517. Back to cited text no. 12 13. Han LP, Dong ZM, Qiao YH, Nesland JM, Suo ZH. Expression of estrogen receptor subtypes in epithelial ovarian carcinomas. Sichuan Da Xue Xue Bao Yi Xue Ban 2006; 37:606–610. Back to cited text no. 13 14. Thomas C, Gustafsson JÅ. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011; 11:597–608. Back to cited text no. 14 15. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A et al. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009; 114:480–485. Back to cited text no. 15 16. Lee KR. The pathology of surface epithelial-stromal tumors of the ovary. In Crumb CP, Lee KR, editors. Diagnostic gynecologic and obestetric pathology. Boston, Massachusetts: Elsvier and Saunders; 2006. 839–903. Back to cited text no. 16 17. Sobin LH, Wittekind C. TNM classification of malignant tumor. Cancer 2002; 94:2511–2516. Back to cited text no. 17 18. Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P et al. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res 2011; 17:511–518. Back to cited text no. 18 19. Buchynska LG, Nesina IP, Yurchenko NP. Expression of p53, p21WAF1/CIP1, p16INK4a and Кi-67 proteins in serous ovarian tumors. Exp Oncol 2007; 29:49–53. Back to cited text no. 19 20. Jiang JY, Cheung CK, Wang Y, Tsang BK. Regulation of cell death and cell survival gene expression during ovaria follicular development and atresia. Front Biosci 2003; 8:222–237. Back to cited text no. 20 21. Berisha B, Schams D. Ovarian function in ruminants. Domest Anim Endocrinol 2005; 29:305–317. Back to cited text no. 21 22. Gadducci A, Cosio S, Tana R, Genazzani AR. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 2009; 69:12–27. Back to cited text no. 22 23. De Stefano I, Zannoni GF, Prisco MG, Fagotti A, Tortorella L, Vizzielli G et al. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome inadvanced serous ovarian cancer. Gynecol Oncol 2011; 122:573–579. Back to cited text no. 23 24. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 2008; 111:144–145. Back to cited text no. 24 25. 25.Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol 2015; 5:19. Back to cited text no. 25 26. Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A, Saito S. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol 2001; 25:667–672. Back to cited text no. 26 27. Sharifi N, Yousefi Z, Saeed S, Bahreini M. Prognostic values of estrogen and progesterone expression receptors in ovarian papillary serous carcinoma. Iran J Pathol 2009; 4:9–12. Back to cited text no. 27 28. Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P, Lazennec G. Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer Res 2004; 64:5861–5869. Back to cited text no. 28 29. Cunat S, Ho V, Mann P, Pujol P. Estrogen and epithelial ovarian cancer. Gynecol Oncol 2004; 94:25–32. Back to cited text no. 29 30. Yang XY, Xi MR, Yang KX, Yu H. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma. Gynecol Oncol 2009; 113:99–104. Back to cited text no. 30 31. Hecht JL, Kotsopoulos J, Hankinson SE. Relationship between epidemiological risk and hormone receptor expression in ovarian cancer: results from the Nurses’ Health Study. Cancer Epidemiol Biomark Prev 2009; 18:1–14. Back to cited text no. 31 32. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Gayther S. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish MALOVA ovarian cancer study. Gyencol Oncol 2007; 106:318–324. Back to cited text no. 32 33. Arias-Pulido H, Smith HO, Jost NE, Bocklage T, Quall CR, Chavez A, Verschraegen CF. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancer and low malignant potential tumors. Gynecol Oncol 2009; 114:480–485. Back to cited text no. 33 34. Geisler JP, Buller E, Manahan KJ. Estregon receptor alpha and beta expression in a case matched series of srous and endometroid adenocarcinoma of the ovary. Eur J Gynaecol Oncol 2008; 29:126–128. Back to cited text no. 34 35. Tanvanich S, Tangjitgamol S, Manusirivithaya S. Expression of estrogen receptor and progesterone receptor in epithelial ovarian tumors. Vajira Med J 2008; 52:249–256. Back to cited text no. 35 36. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007; 193:421–433. Back to cited text no. 36 37. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519–2529. Back to cited text no. 37

Full Text link